Servier presents its 2019/20 annual results, its R&D strategy and pipeline

19/01/2021

At a press conference held online on January 19, 2021, Olivier Laureau, President of Servier, Pascal Lemaire, Executive Vice President, Finance, and Claude Bertrand, Executive Vice President R&D, presented the financial results and the Group’s Research and Development strategy and pipeline for financial year 2019/20.

Group revenue for the 2019/20 financial year amounted to €4.7 billion, an increase of 1.6% at real exchange rates, compared with the previous financial year. Revenue from brand-name medicines represents 70% of the Group revenue, and generics 30%. This progression is mainly due to the increase in the volume of brand-name medicine sales (+2.9% in boxes distributed compared with the previous financial year) and a good performance in oncology.

“During the Covid-19 global health crisis, Servier was able to adapt to maintain the production and distribution of its medicines so that they remain available to patients, while ensuring the health and safety of its employees. Results for the 2019/20 financial year are in line with our objectives […],” comments Pascal Lemaire, Executive Vice President Finance at Servier.

 

The conference was also the opportunity to present Servier’s strategic objectives: “The Group has set ambitious objectives for 2025 that aim to improve its current performance in order to develop new medicines to the benefit of patients,” states Olivier Laureau, President of Servier. “This is why we accelerate the Group’s global transformation dynamic, across all its business segments. This, in order to be ever more committed to therapeutic progress and to guarantee our sustainability and our independence.”

 

Claude Bertrand, Executive Vice President, R&D, highlighted the transformation of R&D activities, recently initiated in order to foster innovation and meet the Group’s 2025 strategic objectives, in particular that of launching a new molecular entity every three year: “[…]  An initial action plan has been deployed within R&D. This plan focuses on de novo innovation, which consists of accelerating the discovery and development of new medicines to meet therapeutic needs in oncology, neurology, and immuno-inflammation. It is also based on innovation linked to medicine life-cycle management, through incremental research, particularly for medicines in the cardio-metabolic field. This transformation project is based on the commitment and adaptability demonstrated by all our teams since the beginning of the health crisis.”

 

 

Focus on a promising pipeline

With 27 projects in clinical development, including 16 new molecular entities, and 33 research projects[1], the result of a significant and continuous investment in R&D (23% of brand-name revenue), Servier concentrates its research and development efforts in therapeutic areas where the need is greatest.

 

 

 

 

Read the press release

 

[1] Data as of January 2021